Inhibikase Therapeutics, Inc.
IKT · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $146 | $176 | $196 | $225 |
| - Cash | $38 | $78 | $73 | $56 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $108 | $98 | $123 | $169 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| EBITDA | -$12 | -$11 | -$16 | -$12 |
| % Margin | – | – | – | – |
| Net Income | -$12 | -$10 | -$14 | -$12 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.133 | -0.11 | -0.15 | -0.17 |
| % Growth | -20.5% | 26.7% | 11.8% | – |
| Operating Cash Flow | -$11 | -$6 | -$4 | -$5 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$11 | -$6 | -$4 | -$5 |